-
261
BUNDA: KISAH CINTA 2 KODI BY ASMA NADIA: A STRUCTURALISM STUDY
Published 2020-10-01Get full text
Article -
262
-
263
Structure- and Ligand-Based Virtual Screening for Identification of Novel TRPV4 Antagonists
Published 2024-12-01Get full text
Article -
264
Serum Cystatin S (CST4): A Novel Prognostic Marker for Gastric Cancer
Published 2025-01-01Get full text
Article -
265
Studying the impact of chitosan salicylaldehyde/schiff base/CuFe2O4 in PC3 cells via theoretical studies and inhibition of PI3K/AKT/mTOR signalling
Published 2025-02-01“…The mRNA expression levels of PI3K, AKT, mTOR, and CCND1 were examined in PC3-treated cells by using QRT-PCR, and the results demonstrated that, by down-regulating the expression levels of these genes, chitosan salicylaldehyde/CuFe2O4 significantly affected prostate cancer cell proliferation, progression, and autophagy more than chitosan salicylaldehyde. …”
Get full text
Article -
266
Anti-allergic effect of 5,7-dihydroxy-4-methylcoumarin in IgE-mediated RBL-2H3 cells and PCA murine model
Published 2025-01-01Get full text
Article -
267
Photocatalytic Degradation of 2,4-Dichlorophenol by TiO2 Intercalated Talc Nanocomposite
Published 2019-01-01Get full text
Article -
268
-
269
-
270
Citrullinated IGF2BP1 promotes rheumatoid synovial aggression via increasing the mRNA stability of SEMA3D
Published 2025-01-01Get full text
Article -
271
-
272
A Novel HPNVD Descriptor for 3D Local Surface Description
Published 2024-12-01Get full text
Article -
273
Pediatric hypertrophic cardiomyopathy caused by a novel TNNI3 variant
Published 2024-03-01Get full text
Article -
274
Rhyme or Reason: Three Patterns of Poetic Interference in the British Crime Novel
Published 2004-12-01Get full text
Article -
275
ADAMTS1, CRABP1, and NR3C1 Identified as Epigenetically Deregulated Genes in Colorectal Tumorigenesis
Published 2006-01-01“…Among 20 colon cancer cell lines, hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). …”
Get full text
Article -
276
-
277
-
278
-
279
-
280
Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
Published 2025-01-01“…After treatment with 177Lu-iPD-L1 (0.4 Bq/cell), flow cytometry results showed a significant decrease in cell viability of 4T1 cells (dead 56.2%) compared to 177LuCl3 (dead 34.2%) and untreated cells (dead 9.4%). …”
Get full text
Article